Elicio Therapeutics (ELTX) Assets (2020 - 2026)

Elicio Therapeutics has reported Assets for 7 years, with the latest figure at $22.7 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 19.48% year-over-year to $22.7 million; the trailing twelve-month figure through Mar 2026 stood at $22.7 million (down 19.48% YoY), and the FY2025 full-year result was $25.9 million, down 8.22% from the prior year.
• Assets for Q1 2026 stood at $22.7 million, down from $25.9 million in the prior quarter.
• The five-year high for Assets was $81.3 million in Q1 2022, with the low at $15.8 million in Q2 2024.
• Historically, Assets has averaged $36.2 million across 5 years, with a median of $28.3 million in 2025.
• Annual changes were most pronounced in 2022 — Assets sank 76.52% — and 2025, when it surged 87.48%.
• Elicio Therapeutics' Assets stood at $22.7 million in 2022, then grew by 19.78% to $27.1 million in 2023, then gained by 3.8% to $28.2 million in 2024, then slipped by 8.22% to $25.9 million in 2025, then slipped by 12.27% to $22.7 million in 2026.
• The last three Assets figures came in at $22.7 million (Q1 2026), $25.9 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.